INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Globus Medical, Inc. - GMED

Core Insights - Pomerantz LLP is investigating claims on behalf of investors of Globus Medical, Inc. regarding potential securities fraud or unlawful business practices by the company and its officers [1] - Globus Medical reported financial results for Q1 2025, with non-GAAP earnings per share of $0.68, missing consensus estimates by $0.06, and revenue of $598.12 million, which was $27.78 million below expectations and represented a 1.4% year-over-year decline [3] - Following the disappointing financial results, Globus's stock price fell by $16.64 per share, or 22.96%, closing at $55.82 on May 9, 2025 [3] Financial Performance - Non-GAAP earnings per share for Q1 2025 were reported at $0.68, missing estimates by $0.06 [3] - Revenue for the same period was $598.12 million, falling short of consensus estimates by $27.78 million and showing a 1.4% decline compared to the previous year [3] - The decline in performance was attributed to softer deal closures, supply chain disruptions, and timing issues with international distributor orders [3] Stock Market Reaction - The stock price of Globus Medical experienced a significant drop of $16.64 per share, equating to a 22.96% decrease [3] - The closing price after the drop was $55.82 per share on May 9, 2025 [3]